Topic Hub

Longevity Rx — Head-to-Head Comparisons

12 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.

12articles

91keywords mapped

2026-05-26latest review

Explore

Longevity Rx — Head-to-Head Comparisons library

Showing 12 of 12 clinical reviews.

Access2026-05-26

NMN/NR vs Low-Dose Naltrexone: Cost and Access Compared

A head-to-head comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone on price, insurance coverage, pharmacy access, and regulatory status for longevity-focused patients.

Read clinical review

Comparisons2026-05-26

NMN/NR vs Low-Dose Naltrexone: Head-to-Head Efficacy for Longevity

A clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone (LDN) for longevity, covering mechanisms, trial data, dosing, safety, and when each agent fits best.

Read clinical review

Safety2026-05-25

NMN/NR vs Low-Dose Naltrexone: Side-Effect Profile Head-to-Head

A clinical comparison of the side-effect profiles of nicotinamide mononucleotide/riboside (NMN/NR) and low-dose naltrexone (LDN), covering GI tolerance, sleep disruption, hepatic safety, and long-term risk data.

Read clinical review

Comparisons2026-05-27

NMN/NR vs Low-Dose Naltrexone: Switching Between Them

A clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone for longevity, including when and how to switch between them safely.

Read clinical review

Access2026-05-25

Rapamycin (Sirolimus) vs Low-Dose Naltrexone: Cost and Access Head-to-Head

A clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) for longevity, covering pricing, prescribing access, insurance coverage, evidence base, and practical switching guidance.

Read clinical review

Comparisons2025-01-28

Rapamycin (Sirolimus) vs Low-Dose Naltrexone: Head-to-Head Efficacy

A detailed clinical comparison of rapamycin (sirolimus) and low-dose naltrexone for longevity, immune modulation, and inflammation. Learn which drug fits which patient profile, what the evidence actually shows, and when clinicians combine or switch between them.

Read clinical review

Safety2025-01-28

Rapamycin (Sirolimus) vs Low-Dose Naltrexone: Side-Effect Profile Head-to-Head

A clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) side-effect profiles for longevity and immune-modulation use, with trial data, dosing context, and prescriber guidance.

Read clinical review

Comparisons2026-05-25

Rapamycin (Sirolimus) vs Low-Dose Naltrexone: Switching Between Them

Evidence-based comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) for longevity, including when and how to switch between them safely.

Read clinical review

Access2026-05-26

Rapamycin (Sirolimus) vs NMN/NR: Cost and Access Head-to-Head Comparison

A clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) covering cost, access, insurance coverage, evidence quality, and practical prescribing considerations for longevity medicine.

Read clinical review

Comparisons2026-05-25

Rapamycin (Sirolimus) vs NMN/NR: Head-to-Head Efficacy for Longevity

Evidence-based comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, covering mechanism, clinical trial data, dosing, safety, and practical guidance.

Read clinical review

Safety2026-05-25

Rapamycin (Sirolimus) vs NMN/NR: Side-Effect Profile Head-to-Head

A clinical comparison of the side-effect profiles of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, including trial data, dosing considerations, and safety monitoring.

Read clinical review

Comparisons2026-05-26

Rapamycin (Sirolimus) vs NMN/NR: Switching Between Them

A clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, including when and how to switch between these interventions.

Read clinical review